Clinical Trials Sponsored by ETOP IBCSG Partners Foundation

Total 66 results

ETOP IBCSG Partners Foundation

Completed

TRial on the Endocrine Activity of Neoadjuvant Degarelix (TREND)

Breast Cancer Invasive Nos

Italy
ETOP IBCSG Partners Foundation

Completed

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer (12-93)

Breast Cancer

Switzerland, Australia, Slovenia, Italy, Sweden, South Africa, New Zealand
ETOP IBCSG Partners Foundation

Completed

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer (10-93)

Breast Cancer

Switzerland, Australia, Slovenia, Italy, Sweden, Hungary, Israel, South Africa, New Zealand
ETOP IBCSG Partners Foundation

Withdrawn

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

Breast Cancer | Osteoporosis

Switzerland
ETOP IBCSG Partners Foundation

Completed

MEtronomic TrEatment Option in Advanced bReast cAncer (METEORA-II)

Breast Cancer

Italy
ETOP IBCSG Partners Foundation

Completed

Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07 (SOLE-EST)

Breast Cancer

Australia, Belgium
ETOP IBCSG Partners Foundation

Terminated

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer (CASA)

Breast Cancer

Italy, Australia, Belgium, Switzerland, Slovenia, Hungary, Sweden, New Zealand, Romania
ETOP IBCSG Partners Foundation

Completed

Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98

Breast Cancer | Fatigue | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment

Belgium, Switzerland, United Kingdom, Australia, Italy, New Zealand
ETOP IBCSG Partners Foundation

Completed

Afatinib in NSCLC With HER2 Mutation (NICHE)

NSCLC

Switzerland, Germany, Spain, Netherlands
ETOP IBCSG Partners Foundation

Completed

Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02 (SOFT-EST)

Breast Cancer

Spain, Switzerland, Hungary, France, Italy, Peru, Portugal, Sweden
ETOP IBCSG Partners Foundation

Terminated

IBCSG Trial 22-00 Serum Substudy

Breast Cancer

Peru, Italy, Nigeria
ETOP IBCSG Partners Foundation

Completed

Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases (23-01)

Breast Cancer

France, Switzerland, Australia, Peru, Italy, New Zealand, Slovenia, Belgium, Brazil, Denmark
ETOP IBCSG Partners Foundation

Completed

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer (22-00)

Breast Cancer

Italy, Switzerland, Australia, Peru, South Africa, Chile, Belgium, Brazil, Romania, Hungary, Nigeria
ETOP IBCSG Partners Foundation

Completed

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer (15-95)

Breast Cancer

Switzerland, Australia
ETOP IBCSG Partners Foundation

Terminated

Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98

Breast Cancer | Osteoporosis
ETOP IBCSG Partners Foundation

Completed

Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

Breast Cancer | Osteoporosis

France, Italy, Switzerland, Australia, Peru, Spain, New Zealand, South Africa
ETOP IBCSG Partners Foundation
Takeda

Recruiting

Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)

NSCLC, Stage III | ALK-rearrangement

France, Spain, Italy, Poland, United Kingdom
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
ETOP IBCSG Partners Foundation
AstraZeneca

Recruiting

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)

Non-small Cell Lung Cancer | Oligometastasis | Stage IV

Switzerland, Netherlands, Spain, Italy
ETOP IBCSG Partners Foundation
USZ Foundation

Recruiting

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE)

Melanoma | Non-Small Cell Lung Cancer

Switzerland, Netherlands, Italy, United Kingdom
ETOP IBCSG Partners Foundation
Pfizer

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Breast Cancer Recurrent

Switzerland, Italy, France, Spain, Hungary, Austria
ETOP IBCSG Partners Foundation
Biodesix, Inc.

Completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (EMPHASIS)

Carcinoma, Non-Small-Cell Lung

Ireland, Switzerland, Denmark, Spain, United Kingdom, Belgium, Hungary, Greece, Israel, Austria, Italy, Netherlands
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
ETOP IBCSG Partners Foundation
NSABP Foundation Inc

Completed

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer (CALOR)

Breast Cancer

Spain, United States, Australia, Belgium, Switzerland, Canada, Peru, Netherlands, Hungary, South Africa
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Recruiting

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (PREcoopERA)

Breast Cancer

Ireland, Italy, Germany, Spain, Hungary, France, Sweden, Switzerland
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer (PYTHIA)

Metastatic Breast Cancer

United Kingdom, Belgium, Italy
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA)

Metastatic Breast Cancer

France, Austria, Belgium, Australia, Italy
ETOP IBCSG Partners Foundation
Roche Pharma AG

Active, not recruiting

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Singapore, Spain, Korea, Republic of, Switzerland, Germany
ETOP IBCSG Partners Foundation
Amgen; Eisai Inc.

Withdrawn

AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC (AMBER)

Metastatic Non Small Cell Lung Cancer | KRAS G12C

Spain, Switzerland, Austria, Germany
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP)

Metastatic Breastcancer

Spain, Ireland, Italy, Switzerland, Slovenia, Belgium
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (SOLE)

Breast Cancer

France, Spain, Switzerland, Australia, Belgium, Austria, Peru, Germany, Italy, Japan, New Zealand, Sweden, Denmark, India, United States, Chile, Russian Federation, United Kingdom, Hungary, South Africa
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation
GlaxoSmithKline; Development Limited

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)

SCLC,Extensive Stage | SLFN11-positive

Switzerland, France, Spain, Italy
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, United Kingdom, Belgium
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Active, not recruiting

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso)

Pleural Mesothelioma Malignant Advanced

Switzerland, United Kingdom, Belgium, Spain, France, Italy
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
ETOP IBCSG Partners Foundation
Pfizer; Hoffmann-La Roche

Completed

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

France, Switzerland, Belgium, Italy
ETOP IBCSG Partners Foundation
Spanish Lung Cancer Group

Completed

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (BELIEF)

Lung Cancer

Spain, Ireland, United Kingdom, Switzerland, France, Germany, Greece, Italy
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
ETOP IBCSG Partners Foundation
UNICANCER; Danish Breast Cancer Cooperative Group

Completed

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98)

Breast Cancer

France, Denmark, Switzerland
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 (TEXT-Bone)

Breast Cancer | Osteoporosis

Belgium, Australia, Switzerland
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Terminated

Premenopausal Endocrine Responsive Chemotherapy Trial (PERCHE)

Breast Cancer

Switzerland, Italy, Hungary
University Hospital, Basel, Switzerland
ETOP IBCSG Partners Foundation; Austrian Breast Cancer Study Group

Recruiting

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)

Node-positive Breast Cancer

Greece, Switzerland, Hungary, Austria, Germany, Italy, Lithuania, Argentina, Croatia
European Organisation for Research and Treatment...
ETOP IBCSG Partners Foundation

Active, not recruiting

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM)

Thymic Carcinoma | Thymoma Type B3

Netherlands, Spain, France, Belgium, United Kingdom, Switzerland
European Organisation for Research and Treatment...
ETOP IBCSG Partners Foundation

Completed

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access (SPECTAlung)

Any Stage of Lung Cancer (Any Histotype) | Any Stage of Malignant Pleural Mesothelioma | Any Stage of Any Thymic Malignancy

Spain, Belgium, Ireland, Slovenia, France, United Kingdom, Poland, Italy, Switzerland
ETOP IBCSG Partners Foundation
European Organisation for Research and Treatment of Cancer - EORTC; Amgen

Terminated

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (SPLENDOUR)

Lung Cancer Non-small Cell Stage IV

Ireland, Spain, Switzerland, United Kingdom, France, Austria, Slovenia, Belgium, Italy, Germany, Poland
Spanish Breast Cancer Research Group
Novartis Pharmaceuticals; ETOP IBCSG Partners Foundation; Breast International...

Active, not recruiting

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (ALPHABET)

Advanced Breast Cancer

Spain, Netherlands, France, Italy, Austria, Switzerland

Clinical Trials Sponsored by ETOP IBCSG Partners Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations